ArticleEndocrine2024
Screening for primary aldosteronism on and off interfering medications.
Article in Endocrine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Primary Aldosteronism：a Prospective Study
Overnight Dexamethasone in Primary Aldosteronism Screening in Patients on Interfering Therapy (the ODEPRASC Study)
Steroids-Based Screening for Primary Aldosteronism
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Renal disorders in Autoimmune Polyendocrinopathy Candidiasis Ectodermal dystrophy (APECED): a systematic review.BMC pediatrics · 2025Pooled it
- Improving Prediction of Complications Post-Proton Therapy in Lung Cancer Using Large Language Models and Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Performance of Primary Aldosteronism Screening Tests Before Washout of Dihydropyridine Calcium Channel Blockers: An Exploratory Retrospective Study.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Assessment of markers of primary aldosteronism in systemic sclerosis and their relationships with renal and cardiovascular outcomes.RMD open · 2026Article
- Primary aldosteronism.Nature reviews. Disease primers · 2026Review
- Transgenesis in Drug Discovery: Enhancing Target Identification and Validation.Molecular biotechnology · 2026Review
- Cefadroxil-Mupirocin Integrated Electrospun Nanofiber Films for Burn Wound Therapy.Current drug delivery · 2026Article
- Comparison of different criteria of captopril challenge test for the diagnosis of primary aldosteronism.Endocrine · 2025Article
- Diagnostic performance of 24-hour urinary aldosterone for primary aldosteronism in patients with or without discontinuation of antihypertensive medications.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Overnight Dexamethasone in Primary Aldosteronism Screening in Patients on Interfering Therapy (ODEPRASC): A Diagnostic Interpretability Study Protocol.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Kidney cancer diagnosis and surgery selection by double decker convolutional neural network from CT scans combined with great wall construction algorithm.Abdominal radiology (New York) · 2025Article
- Universal Screening for Primary Aldosteronism in Hypertensive Patients: A 2025 Taipei Positional Paper.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Advanced QSPR modeling of profens using machine learning and molecular descriptors for NSAID analysis.Scientific reports · 2025Article
- An advanced network pharmacology investigation of Shufeng Jiedu formula in the treatment for respiratory tract infection based on LC-MS, data mining, molecular docking, and molecular dynamic simulation.Briefings in bioinformatics · 2025Article
- A graph-based computational approach for modeling physicochemical properties in drug design.Scientific reports · 2025Article
- Pharmacological, computational, and mechanistic insights into triptolide's role in targeting drug-resistant cancers.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Identification and functional characterization of hub genes CLTA, EDIL3, HAPLN1, and HIP1 as diagnostic biomarkers and therapeutic targets in thyroid cancer and Hashimoto's thyroiditis.Clinical and experimental medicine · 2025Article
- Harnessing the angiogenic potential of adipose-derived stromal vascular fraction cells with perfusion cell seeding.Stem cell research & therapy · 2025Article
- Fine-tuned deep learning models for early detection and classification of kidney conditions in CT imaging.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectiveTo determine whether antihypertensives will affect diagnostic accuracy of the aldosterone-to-renin ratio (ARR) to an extent that is clinically relevant.
methodsConfirmatory tests were used to confirm or exclude PA diagnosis. Area under the receiver operating characteristic curve (AUC), specificity and sensitivity of ARR performance in different conditions were calculated.
results208 PA and 78 essential hypertension (EH), and 125 PA and 206 EH patients, were included in the retrospective and prospective cohort, respectively. AUC of ARR on interfering medications was comparable to ARR off interfering medications (retrospective: 0.82 vs. 0.87, p = 0.20; prospective: 0.78 vs. 0.84, p = 0.07). At a threshold of 20 pg/μIU, the sensitivity of ARR on interfering medications was lower (11.1-23.2%) while the specificity was higher (10.2-15.2%) than ARR off interfering medications. However, when the ARR threshold on interfering medications was lowered to 10 pg/μIU, both the sensitivity (retrospective: 0.91 vs. 0.90, p = 0.61; prospective: 0.86 vs. 0.82, p = 0.39) and specificity (retrospective: 0.49 vs. 0.59, p = 0.20; prospective: 0.58 vs. 0.66, p = 0.10) were comparable to the ARR threshold off interfering medications.
conclusionUsing ARR to screen for PA whilst taking interfering antihypertensive drugs is feasible in most cases, but the ARR threshold needs to be reduced.
trial registrationClinicalTrials.gov identifier: NCT04991961.
Indexed as
Identifiers
37796417What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.